Myosin Therapeutics

Myosin Therapeutics is an early-stage, private biotech company developing a novel class of therapeutics that target molecular motors, a largely unexplored mechanism in drug discovery. The company's platform focuses on disrupting the cellular mechanics of cancer progression and dysregulated brain plasticity, moving beyond traditional signaling pathway inhibition. With a lead Phase 1/2 trial for glioblastoma set to begin in 2026 and a seasoned leadership team with deep drug development expertise, Myosin is positioning itself to tackle high-unmet-need conditions in oncology and neuroscience. The company is currently pre-revenue and in the pre-clinical to early clinical stage of development.

Small molecule inhibitors targeting non-muscle myosin II (NMII), a molecular motor protein, to disrupt cellular mechanics in disease processes like tumor progression and dysregulated brain plasticity.

Competition is indirect, as Myosin's mechanism is novel. In GBM and PDAC, it will compete against other novel modalities (e.g., immunotherapies, targeted therapies) and standard of care. The broader competitive threat would come from other biotechs exploring cytoskeletal targets, though targeting myosin motors appears to be a niche and emerging area with few disclosed competitors.